Its revenue increased 28%, both sequentially and from the year-ago period, to ₹220.9 crore in the June quarter.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) of ₹70.2 crore was up 9.7% from the previous year’s ₹63.6 crore and 10% from the previous quarter’s ₹64 crore.Its margins contracted to 31.8% from 37.1% in the earlier quarter and from 36.9% in the previous year.
Allegra, DePURA, Avil and Combiflam are the products in the company’s portfolio.
Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two previously recalled products.The company relaunched DePURA 60k and Combiflam after their suspension. The two were voluntarily recalled last year.
It also introduced a new product. It launched Allegra D during the half year.
The company commenced its export operations as well.
Also, other legacy brands such as Avil and DePURA continue to hold consumer trust and relevance in categories.
Shares of Sanofi Consumer Healthcare gained 15% to hit an intraday high of ₹5,512 apiece on Tuesday. The stock was up 9.5% at ₹5,248 apiece at 11.55 pm.
Also Read: IndusInd Bank shares surge over 6% after Rajiv Anand becomes MD & CEO for three years
